Nystrom T, Toresson Grip E, Gunnarsson J, Casajust P, et al. Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study. Diabetes Obes Metab 2023;25:261-271.
PMID: 36097728